AgomAb Therapeutics

{
  "events": [
    {
      "kind": "capital_increase",
      "after_eur": 303057813.91,
      "delta_eur": 64467.189999997616,
      "before_eur": 302993346.72,
      "contribution_type": "geld"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0674.527.310",
    "name_full": "AgomAb Therapeutics"
  }
}

{
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "name_change": {
    "new": "",
    "old": "",
    "changed": false
  },
  "seat_change": {
    "changed": false
  },
  "object_change": {
    "changed": false
  },
  "subject_company": {
    "kbo": "0674.527.310",
    "name_full": "AgomAb Therapeutics"
  },
  "legal_form_change": {
    "new": "",
    "old": "Naamloze vennootschap",
    "changed": false
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "after_eur": 303057813.91,
      "delta_eur": 64467.19,
      "before_eur": 302993346.72,
      "subscribers": [
        {
          "kbo": null,
          "rrn": null,
          "kind": "org",
          "name": "Employee Stock Optie Warrants",
          "share_class": "gewone",
          "liberation_pct": 100.0,
          "contribution_kind": "geld",
          "n_shares_subscribed": 21645,
          "contribution_amount_eur": 0.01
        },
        {
          "kbo": null,
          "rrn": null,
          "kind": "org",
          "name": "2022 Employee Stock Optie Warrants",
          "share_class": "gewone",
          "liberation_pct": 100.0,
          "contribution_kind": "geld",
          "n_shares_subscribed": 21645,
          "contribution_amount_eur": 52.13
        },
        {
          "kbo": null,
          "rrn": null,
          "kind": "org",
          "name": "2023 Employee Stock Optie Warrants",
          "share_class": "gewone",
          "liberation_pct": 100.0,
          "contribution_kind": "geld",
          "n_shares_subscribed": 21645,
          "contribution_amount_eur": 52.13
        },
        {
          "kbo": null,
          "rrn": null,
          "kind": "org",
          "name": "2024 Employee Stock Optie Warrants",
          "share_class": "gewone",
          "liberation_pct": 100.0,
          "contribution_kind": "geld",
          "n_shares_subscribed": 21645,
          "contribution_amount_eur": 52.13
        }
      ],
      "share_emission": {
        "agio_eur": null,
        "share_form": "no_nominal_value",
        "share_class": "gewone",
        "n_new_shares": 28229,
        "with_new_shares": true,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": "geld",
      "paid_up_delta_eur": 64467.19,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "share_class_creation",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": null,
        "n_new_shares": null,
        "with_new_shares": false,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    }
  ],
  "notary": {
    "name": "Tim CARNEWAL",
    "firm_city": null,
    "firm_name": "BERQUIN NOTARISSEN",
    "office_city": "Brussel",
    "is_associated": true
  },
  "act_meta": {
    "language": "nl",
    "pub_date": "2026-04-17",
    "filing_date": "2026-04-15",
    "act_kind_objet": "Onderwerp akte:"
  },
  "decision": {
    "body": "bijzondere_algemene_vergadering",
    "act_date": "2026-03-12",
    "unanimous": null,
    "under_authorized_capital": false,
    "underlying_resolution_date": null
  },
  "bedrijfsrevisor": null,
  "subject_company": {
    "kbo": "0674.527.310",
    "name_full": "AgomAb Therapeutics",
    "legal_form": "Naamloze vennootschap",
    "is_foreign_registered": false
  },
  "publication_proxy": {
    "kind": "person",
    "org_kbo": null,
    "org_name": null,
    "person_name": "Tim CARNEWAL",
    "org_rep_person_name": null,
    "person_role_at_subject": null
  },
  "co_filed_documents": [
    "uitgifte van de akte",
    "de geco\u00F6rdineerde tekst van statuten",
    "ESOP plan"
  ],
  "shareholders_after": [],
  "share_classes_after": [
    {
      "n_shares": 49247975,
      "class_name": "Gewone Aandelen",
      "capital_share_eur": 303057813.91,
      "voting_rights_per_share": 1.0
    }
  ]
}

{
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "statute_change": {
    "name_change": false,
    "seat_change": false,
    "object_change": false,
    "effective_date": "2026-03-12",
    "legal_form_change": false
  },
  "bedrijfsrevisor": null,
  "subject_company": {
    "kbo": "0674.527.310",
    "name_full": "AGOMAB THERAPEUTICS",
    "legal_form": "NV"
  },
  "signature_regime": null,
  "special_mandates": [],
  "governance_change": {
    "admin_delegated_added": []
  }
}

{
  "notary": {
    "name": "Tim CARNEWAL",
    "firm_city": null,
    "firm_name": "BERQUIN NOTARISSEN",
    "office_city": "Brussel",
    "is_associated": true
  },
  "act_meta": {
    "language": "nl",
    "pub_date": "2026-04-17",
    "filing_date": "2026-04-15",
    "act_kind_objet": "KAPITAAL, AANDELEN, STATUTEN (VERTALING, COORDINATIE, OVERIGE WIJZIGINGEN)"
  },
  "decision": {
    "body": "bijzondere_algemene_vergadering",
    "act_date": "2026-03-12",
    "unanimous": null
  },
  "statute_change": {
    "kinds": [
      "translation",
      "coordination",
      "other"
    ],
    "scope": null,
    "trigger": null,
    "language_after": null,
    "language_before": null
  },
  "bedrijfsrevisor": null,
  "subject_company": {
    "kbo": "0674.527.310",
    "name_full_after": "AgomAb Therapeutics",
    "legal_form_after": "Naamloze vennootschap",
    "name_full_before": "AgomAb Therapeutics",
    "current_zetel_raw": "Posthoflei 1 bus 6 2600 Antwerpen",
    "legal_form_before": "Naamloze vennootschap"
  },
  "special_mandates": [],
  "articles_modified": [
    {
      "summary": "De tekst van artikel 5 over het kapitaal wordt vervangen door een nieuwe tekst die de kapitaalverhoging en de uitgifte van nieuwe aandelen beschrijft.",
      "new_text": "5.1. Het kapitaal van de Vennootschap bedraagt driehonderdendrie miljoen zevenenvijftigduizend achthonderddertien euro \u00E9\u00E9nennegentig cent (EUR 303.057.813,91). Het is verdeeld in negenenveertig miljoen tweehonderdzevenenveertigduizend negenhonderdvijfenzeventig (49.247.975) aandelen op naam zonder vermelding van nominale waarde, waarbij elk aandeel een gelijk deel van het kapitaal vertegenwoordigt",
      "change_kind": "replaced",
      "article_title": "KAPITAAL",
      "article_number": "5"
    }
  ],
  "governance_change": null,
  "publication_proxy": {
    "kind": "person",
    "org_kbo": null,
    "org_name": null,
    "person_name": "Tim CARNEWAL",
    "org_rep_person_name": null
  },
  "co_filed_documents": [
    "een uitgifte van de akte",
    "de geco\u00F6rdineerde tekst van statuten",
    "ESOP plan"
  ],
  "shareholder_rights": null,
  "voorwerp_change_summary": null,
  "capital_structure_change": {
    "operations": [
      "capital_increase_cash",
      "share_class_creation"
    ],
    "split_ratio": null,
    "shares_after": 49247975,
    "shares_before": null,
    "capital_after_eur": 303057813.91,
    "capital_before_eur": 302993346.72,
    "share_classes_after": [
      {
        "count": 49247975,
        "label": "gewone aandelen",
        "rights_summary": "Iedere aandeel biedt dezelfde rechten en voordelen als de bestaande gewone aandelen.",
        "voting_per_share": null
      }
    ]
  },
  "coordinated_text_lineage": null
}

{
  "events": [
    {
      "kind": "capital_increase",
      "amount": 64467.19,
      "currency": "EUR",
      "after_eur": 303057813.91,
      "delta_eur": 64467.19,
      "before_eur": 302993346.72,
      "amount_type": "kapitaal_effectief",
      "effective_date": "2026-03-12",
      "evidence_quote": "Het kapitaal werd verhoogd met een bedrag van 64.467,19 EUR, en gebracht van 302.993.346,72 EUR op 303.057.813,91 EUR.",
      "contribution_type": "cash"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0674.527.310",
    "name_full": "AGOMAB THERAPEUTICS",
    "legal_form": "NV"
  }
}

{
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "statute_change": {
    "name_change": false,
    "seat_change": false,
    "object_change": false,
    "effective_date": "2026-03-04",
    "legal_form_change": false
  },
  "bedrijfsrevisor": null,
  "subject_company": {
    "kbo": "0674.527.310",
    "name_full": "AGOMAB THERAPEUTICS",
    "legal_form": "NV"
  },
  "signature_regime": null,
  "special_mandates": [],
  "governance_change": {
    "admin_delegated_added": []
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "amount": 2973096.56,
      "currency": "EUR",
      "after_eur": 302993346.72,
      "delta_eur": 2973096.56,
      "before_eur": 300020250.16,
      "amount_type": "kapitaal_effectief",
      "effective_date": "2026-03-04",
      "evidence_quote": "ingevolge de totstandkoming van de betrokken kapitaalverhoging in het kader van de IPO Kapitaalverhoging, het kapitaal van de Vennootschap EUR 302.993.346,72 bedraagt",
      "contribution_type": "cash"
    },
    {
      "kind": "capital_increase",
      "amount": 3685073.35,
      "currency": "EUR",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "amount_type": "uitgiftepremie",
      "effective_date": "2026-03-04",
      "evidence_quote": "een bedrag van in totaal EUR 3.685.073,35 als uitgiftepremie",
      "contribution_type": "cash"
    },
    {
      "kind": "capital_increase",
      "amount": 302993346.72,
      "currency": "EUR",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "amount_type": "kapitaal_toegestaan",
      "effective_date": "2026-03-04",
      "evidence_quote": "De raad van bestuur mag het kapitaal van de vennootschap in \u00E9\u00E9n of meerdere malen verhogen met een maximum totaalbedrag van driehonderdtwee miljoen negenhonderddrie\u00EBnnegentigduizend driehonderdzesenveertig euro en twee\u00EBnzeventig eurocent (EUR 302.993.346,72).",
      "contribution_type": null
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0674.527.310",
    "name_full": "AGOMAB THERAPEUTICS",
    "legal_form": "NV"
  }
}

{
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "name_change": {
    "new": "",
    "old": "",
    "changed": false
  },
  "seat_change": {
    "changed": false
  },
  "object_change": {
    "changed": false
  },
  "subject_company": {
    "kbo": "0674.527.310",
    "name_full": "AgomAb Therapeutics"
  },
  "legal_form_change": {
    "new": "Naamloze vennootschap",
    "old": "Naamloze vennootschap",
    "changed": false
  }
}

{
  "notary": {
    "name": "Tim CARNEWAL",
    "firm_city": null,
    "firm_name": "BERQUIN NOTARISSEN",
    "office_city": "Brussel",
    "is_associated": true
  },
  "act_meta": {
    "language": "nl",
    "pub_date": "2026-04-08",
    "filing_date": "2026-04-03",
    "act_kind_objet": "KAPITAAL, AANDELEN, STATUTEN (VERTALING, COORDINATIE, OVERIGE WIJZIGINGEN)"
  },
  "decision": {
    "body": "buitengewone_algemene_vergadering",
    "act_date": "2026-03-03",
    "unanimous": null
  },
  "statute_change": {
    "kinds": [
      "translation",
      "coordination",
      "full_restatement",
      "targeted_amendment",
      "legal_form_change",
      "wvv_adaptation",
      "name_change",
      "object_change",
      "duration_change",
      "share_split",
      "share_consolidation",
      "share_class_creation",
      "language_switch",
      "warrant_exercise_capital_update",
      "board_authorized_capital",
      "governance_restructure",
      "liquidation_preference_introduction",
      "seat_region_change",
      "other"
    ],
    "scope": "full_restatement",
    "trigger": "wvv_adaptation",
    "language_after": "nl",
    "language_before": "nl"
  },
  "bedrijfsrevisor": null,
  "subject_company": {
    "kbo": "0674.527.310",
    "name_full_after": "AgomAb Therapeutics",
    "legal_form_after": "Naamloze vennootschap",
    "name_full_before": "AgomAb Therapeutics",
    "current_zetel_raw": "Posthoflei 1 bus 6 2600 Antwerpen",
    "legal_form_before": "Naamloze vennootschap"
  },
  "special_mandates": [],
  "articles_modified": [
    {
      "summary": "Het kapitaal van de vennootschap wordt vastgesteld op EUR 302.993.346,72, verdeeld in 49.219.746 aandelen op naam zonder nominale waarde.",
      "new_text": "Artikel 5. KAPITAAL.\n5.1. Het kapitaal van de Vennootschap bedraagt driehonderdtwee miljoen\nnegenhonderddrie\u00EBnnegentigduizend driehonderdzesenveertig euro en twee\u00EBnzeventig eurocent\n(EUR 302.993.346,72). Het is verdeeld in negenenveertig miljoen tweehonderdnegentienduizend\nzevenhonderdzesenveertig (49.219.746) aandelen op naam zonder vermelding van nominale\nwaarde, waarbij elk aandeel een gelijk d",
      "change_kind": "replaced",
      "article_title": "KAPITAAL",
      "article_number": "5"
    },
    {
      "summary": "De raad van bestuur mag het kapitaal verhogen met een maximumbedrag van EUR 302.993.346,72 via inbrengen in geld, natura, omzetting van reserves of uitgiftepremies, en mag deze machtiging ook gebruiken voor het uitgiften van andere effecten.",
      "new_text": "Artikel 6. TOEGESTAAN KAPITAAL.\n6.1. De raad van bestuur mag het kapitaal van de vennootschap in \u00E9\u00E9n of meerdere malen\nverhogen met een maximum totaalbedrag van driehonderdtwee miljoen\nnegenhonderddrie\u00EBnnegentigduizend driehonderdzesenveertig euro en twee\u00EBnzeventig eurocent\n(EUR 302.993.346,72).\n6.2. De raad van bestuur mag het kapitaal verhogen door inbrengen in geld of in natura, door\nomzetting ",
      "change_kind": "replaced",
      "article_title": "TOEGESTAAN KAPITAAL",
      "article_number": "6"
    }
  ],
  "governance_change": {
    "organ_kind_after": null,
    "organ_kind_before": null,
    "admin_delegated_added": [
      {
        "name": "Tim Knotnerus",
        "excluded_powers": []
      }
    ],
    "representation_rule_after": null,
    "co_signature_threshold_eur": null,
    "representation_rule_before": null
  },
  "publication_proxy": {
    "kind": "person",
    "org_kbo": null,
    "org_name": null,
    "person_name": "Tim CARNEWAL",
    "org_rep_person_name": null
  },
  "co_filed_documents": [
    "een uitgifte van de akte",
    "de geco\u00F6rdineerde tekst van statuten",
    "het aandelenoptieplan"
  ],
  "shareholder_rights": {
    "quorum_rules_changed": false,
    "liquidation_preference_text": null,
    "voorkeurrecht_rules_changed": true,
    "aandelenoverdracht_restrictions_changed": false
  },
  "voorwerp_change_summary": null,
  "capital_structure_change": {
    "operations": [
      "share_cancellation",
      "share_class_creation",
      "capital_increase_cash",
      "eigen_aandelen_inkoop",
      "eigen_aandelen_vernietigen",
      "wvv_capital_release"
    ],
    "split_ratio": null,
    "shares_after": 49219746,
    "shares_before": null,
    "capital_after_eur": 302993346.72,
    "capital_before_eur": null,
    "share_classes_after": [
      {
        "count": 49219746,
        "label": "gewone aandelen",
        "rights_summary": "Elk aandeel heeft dezelfde rechten en voordelen en pari passu rang als de bestaande en uitstaande aandelen, inclusief dividend- en andere uitkeringsrechten.",
        "voting_per_share": null
      }
    ]
  },
  "coordinated_text_lineage": null
}

{
  "events": [
    {
      "kind": "capital_increase",
      "after_eur": 302993346.72,
      "delta_eur": 2973096.5600000024,
      "before_eur": 300020250.16,
      "contribution_type": "geld"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0674.527.310",
    "name_full": "AgomAb Therapeutics"
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "after_eur": 302993346.72,
      "delta_eur": 2973096.56,
      "before_eur": 300020250.16,
      "subscribers": [
        {
          "kbo": null,
          "rrn": null,
          "kind": "org",
          "name": "Underwriters",
          "share_class": null,
          "liberation_pct": 100.0,
          "contribution_kind": "geld",
          "n_shares_subscribed": 482967,
          "contribution_amount_eur": 7727472.0
        }
      ],
      "share_emission": {
        "agio_eur": 3685073.35,
        "share_form": "no_nominal_value",
        "share_class": null,
        "n_new_shares": 482967,
        "with_new_shares": true,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": 6.16
      },
      "decrease_purpose": null,
      "contribution_type": "geld",
      "paid_up_delta_eur": 2973096.56,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "share_class_creation",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": "2026 ESOP Warrants",
        "n_new_shares": 25419,
        "with_new_shares": true,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": null
    },
    {
      "kind": "statutory_reserve_release",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": null,
        "n_new_shares": null,
        "with_new_shares": false,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": "kapitalisering_reserves",
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null,
      "not_yet_called_eur": null,
      "merger_new_shares_n": null,
      "merger_exchange_ratio": null,
      "distribution_amount_eur": null,
      "statutory_unavailable_equity_op": "convert_to_distributable"
    }
  ],
  "notary": {
    "name": "Tim CARNEWAL",
    "firm_city": null,
    "firm_name": "BERQUIN NOTARISSEN",
    "office_city": "Brussel",
    "is_associated": true
  },
  "act_meta": {
    "language": "nl",
    "pub_date": "2026-04-08",
    "filing_date": "2026-04-03",
    "act_kind_objet": "Onderwerp akte:"
  },
  "decision": {
    "body": "buitengewone_algemene_vergadering",
    "act_date": "2026-03-04",
    "unanimous": null,
    "under_authorized_capital": true,
    "underlying_resolution_date": "2026-02-09"
  },
  "bedrijfsrevisor": null,
  "subject_company": {
    "kbo": "0674.527.310",
    "name_full": "AgomAb Therapeutics",
    "legal_form": "Naamloze vennootschap",
    "is_foreign_registered": false
  },
  "publication_proxy": {
    "kind": null,
    "org_kbo": null,
    "org_name": null,
    "person_name": null,
    "org_rep_person_name": null,
    "person_role_at_subject": null
  },
  "co_filed_documents": [
    "uitgifte van de akte",
    "de geco\u00F6rdineerde tekst van statuten",
    "het aandelenoptieplan"
  ],
  "shareholders_after": [],
  "share_classes_after": [
    {
      "n_shares": 49219746,
      "class_name": "Gewone Aandelen",
      "capital_share_eur": 302993346.72,
      "voting_rights_per_share": null
    }
  ]
}

{
  "events": [
    {
      "kind": "director_out",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Xiaoming Fang",
        "address": null,
        "birth_date": null,
        "profession": null,
        "birth_place": null
      },
      "reason": "de_plein_droit_dissolution",
      "subkind": null,
      "via_org": null,
      "statutory": null,
      "compensated": null,
      "effective_date": "2026-01-16",
      "evidence_quote": "De Raad van Bestuur heeft kennis genomen van, en aanvaardt, het ontslag van bestuurder Xiaoming Fang (als Klasse B Investeerder Bestuurder), met ingang vanaf 16 januari 2026.",
      "decharge_status": null,
      "mandate_duration": null,
      "rep_rotation_new_rep": null,
      "rep_rotation_old_rep": null,
      "effective_date_qualifier": "immediate"
    },
    {
      "kind": "board_snapshot",
      "role": null,
      "person": null,
      "reason": null,
      "subkind": null,
      "via_org": null,
      "statutory": null,
      "compensated": null,
      "effective_date": "2026-01-16",
      "evidence_quote": "Met ingang vanaf 16 januari 2026 is de Raad van Bestuur van Agomab Therapeutics NV als volgt samengesteld:",
      "decharge_status": null,
      "mandate_duration": null,
      "rep_rotation_new_rep": null,
      "rep_rotation_old_rep": null,
      "effective_date_qualifier": "immediate"
    }
  ],
  "notary": {
    "name": null,
    "firm_city": null,
    "firm_name": null,
    "office_city": null,
    "is_associated": false
  },
  "act_meta": {
    "language": "nl",
    "pub_date": "2026-03-11",
    "filing_date": "2026-03-03",
    "act_kind_objet": "Onderwerp akte:"
  },
  "decisions": [
    {
      "body": "raad_van_bestuur",
      "date": "2026-03-02",
      "unanimous": null
    }
  ],
  "is_correction": false,
  "subject_company": {
    "kbo": "0674.527.310",
    "name_full": "Agomab Therapeutics",
    "legal_form": "NV"
  },
  "publication_proxy": {
    "kind": "person",
    "org_kbo": null,
    "org_name": null,
    "person_name": "Tim Knotnerus",
    "org_rep_person_name": null,
    "person_role_at_subject": "CEO Bestuurder"
  },
  "co_filed_documents": [
    "Bijlagen bij het Belgisch Staatsblad - 11/03/2026 - Annexes du Moniteur belge"
  ],
  "corrected_publication_numac": null
}

{
  "events": [],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0674.527.310",
    "name_full": "AGOMAB THERAPEUTICS",
    "legal_form": "NV"
  }
}

{
  "events": [
    {
      "kind": "director_out",
      "role": "Klasse B Investeerder Bestuurder",
      "person": {
        "rrn": null,
        "name": "Xiaoming Fang",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0674.527.310",
    "name_full": "Agomab Therapeutics"
  }
}

{
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "name_change": {
    "new": "",
    "old": "",
    "changed": false
  },
  "seat_change": {
    "changed": false
  },
  "object_change": {
    "changed": false
  },
  "subject_company": {
    "kbo": "0674.527.310",
    "name_full": "AgomAb Therapeutics"
  },
  "legal_form_change": {
    "new": "Naamloze vennootschap",
    "old": "Naamloze vennootschap",
    "changed": false
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "after_eur": 300020250.16,
      "delta_eur": 76948750.00000003,
      "before_eur": 223071500.16,
      "contribution_type": "geld"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0674.527.310",
    "name_full": "AgomAb Therapeutics"
  }
}

{
  "events": [
    {
      "kind": "share_class_creation",
      "_note": "DERDE BESLUIT / vaststelling B: IPO Winstbewijs Conversie. Uitstaande Klasse A Preferent Winstbewijs verplicht geconverteerd in 95.616 Gewone Aandelen ten gunste van argenx BV, zonder uitgifteprijs. Kapitaal ongewijzigd; aantal aandelen 876.522 -\u003E 1.674.138; fractiewaarde 141,32 -\u003E 133,25 EUR.",
      "after_eur": 223071500.16,
      "delta_eur": 0,
      "before_eur": 223071500.16,
      "subscribers": [
        {
          "kbo": null,
          "rrn": null,
          "kind": "company",
          "name": "argenx BV",
          "share_class": "Gewone Aandelen",
          "liberation_pct": null,
          "contribution_kind": "conversie Klasse A Preferent Winstbewijs (geen uitgifteprijs)",
          "n_shares_subscribed": 95616,
          "contribution_amount_eur": 0
        }
      ],
      "share_emission": {
        "agio_eur": null,
        "share_form": "op naam",
        "share_class": "Gewone Aandelen",
        "n_new_shares": 95616,
        "with_new_shares": true,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": 0
      },
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null
    },
    {
      "kind": "share_class_conversion",
      "_note": "VIERDE BESLUIT / vaststelling C: IPO Aandelenconversie. Alle Bevoorrechte D (342.206), C (455.004), B (479.040), A (277.272) en ESOP Gewone Aandelen geconverteerd in gewone aandelen, conversieverhouding 1:1. Soorten vernietigd. Kapitaal EUR 223.071.500,16 en aantal aandelen 1.674.138 ongewijzigd; fractiewaarde blijft 133,25 EUR.",
      "after_eur": 223071500.16,
      "delta_eur": 0,
      "before_eur": 223071500.16,
      "subscribers": [],
      "share_emission": {
        "agio_eur": null,
        "share_form": "op naam",
        "share_class": "gewone aandelen",
        "n_new_shares": null,
        "with_new_shares": false,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null
    },
    {
      "kind": "share_split",
      "_note": "ZESDE BESLUIT / vaststelling E: IPO Aandelensplitsing. Splitsingsratio 21,6450216450216 nieuwe gewone aandelen per 1 bestaand aandeel. 1.674.138 -\u003E 36.236.779 aandelen (n_new_shares = toename 34.562.641). Kapitaal ongewijzigd EUR 223.071.500,16; fractiewaarde 133,25 -\u003E 6,16 EUR. (Vijfde besluit: bevestiging vernietiging Anti-Dilutie A/B/C/D Warrants, geen kapitaaleffect.)",
      "after_eur": 223071500.16,
      "delta_eur": 0,
      "before_eur": 223071500.16,
      "subscribers": [],
      "share_emission": {
        "agio_eur": null,
        "share_form": "op naam",
        "share_class": "gewone aandelen",
        "n_new_shares": 34562641,
        "with_new_shares": true,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null
    },
    {
      "kind": "capital_increase",
      "_note": "TWEEDE BESLUIT / vaststelling F: IPO Kapitaalverhoging in geld met opheffing wettelijk voorkeurrecht. 12.500.000 nieuwe gewone aandelen (elk = 1 ADS) aan USD 16,00 = USD 200.000.000,00 = EUR 169.577.751,40 (Wisselkoers EUR1=USD1,1794 op 6-2-2026). Toewijzing: EUR 76.948.750,00 als kapitaal (delta) \u002B EUR 92.629.001,40 als uitgiftepremie (agio). Per aandeel afgerond EUR 6,16 kapitaal \u002B EUR 7,41 agio; uitgifteprijs ~EUR 13,57 (USD 16,00). Underwriters schreven in voor totaal 12.500.000 aandelen (geen per-underwriter verdeling vermeld); USD 200M gestort bij J.P. Morgan SE Brussels Branch acct BE32549100985502, bankattest 9-2-2026, volledig volgestort. Eindkapitaal EUR 300.020.250,16 / 48.736.779 aandelen.",
      "after_eur": 300020250.16,
      "delta_eur": 76948750,
      "before_eur": 223071500.16,
      "share_emission": {
        "agio_eur": 92629001.4,
        "share_form": "op naam",
        "share_class": "gewone aandelen",
        "n_new_shares": 12500000,
        "with_new_shares": true,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": 13.57
      },
      "decrease_purpose": null,
      "contribution_type": "geld",
      "paid_up_delta_eur": 76948750,
      "n_shares_destroyed": null,
      "_subscribers_dropped_intermediary": 4
    },
    {
      "kind": "warrant_issuance",
      "_note": "TIENDE BESLUIT / vaststelling K: uitgifte 2.908.454 nieuwe 2026 ESOP Warrants (elk recht op 1 nieuw gewoon aandeel), met opheffing voorkeurrecht ten gunste van Begunstigden (managers/werknemers/bestuurders/consultants). = 5% van 58.169.086 volledig verwaterde aandelen (48.736.779 \u002B 6.523.853 bestaande-warrant-aandelen \u002B 2.908.454 nieuwe ESOP). Voorwaardelijke kapitaalverhoging pas bij uitoefening. Looptijd 10 jaar vanaf 15-1-2026. Geen onmiddellijk kapitaaleffect.",
      "after_eur": 300020250.16,
      "delta_eur": 0,
      "before_eur": 300020250.16,
      "subscribers": [],
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": "inschrijvingsrechten (2026 ESOP Warrants)",
        "n_new_shares": 2908454,
        "with_new_shares": false,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": "inschrijvingsrechten_uitgifte",
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null
    },
    {
      "kind": "other",
      "_note": "NEGENDE BESLUIT / vaststelling J: vernietiging van 20.263 (vastgesteld werkelijk aantal) niet-toegekende inschrijvingsrechten onder het \u00272024 (B) Globaal Aandelenoptieplan\u0027 van 4-11-2024 (oorspronkelijk vermeld als 4.552 in besluit, IPO Comit\u00E9 stelde 20.263 vast). Geen kapitaaleffect. Tevens VIJFDE BESLUIT: bevestiging vernietiging Anti-Dilutie A/B/C/D Warrants (geen kapitaaleffect).",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "subscribers": [],
      "share_emission": {
        "agio_eur": null,
        "share_form": null,
        "share_class": "inschrijvingsrechten",
        "n_new_shares": null,
        "with_new_shares": false,
        "nominal_value_eur": null,
        "issue_price_per_share_eur": null
      },
      "decrease_purpose": null,
      "contribution_type": null,
      "paid_up_delta_eur": null,
      "n_shares_destroyed": null
    }
  ],
  "notary": {
    "name": "Tim Carnewal",
    "firm_name": "Berquin Notarissen",
    "office_city": "Brussel",
    "is_associated": true
  },
  "act_meta": {
    "language": "nl",
    "filing_date": "2026-02-24",
    "act_kind_objet": "KAPITAAL, AANDELEN, STATUTEN (VERTALING, COORDINATIE, OVERIGE WIJZIGINGEN)"
  },
  "decision": {
    "body": "buitengewone algemene vergadering",
    "act_date": "2026-01-15",
    "unanimous": null,
    "under_authorized_capital": false
  },
  "bedrijfsrevisor": {
    "waived": false,
    "firm_kbo": null,
    "firm_name": null,
    "mission_type": "commissarisverslag art. 7:155, 7:179, 7:180 en 7:191 W.Venn. (inbreng in geld / opheffing voorkeurrecht / winstbewijsconversie)",
    "individual_name": null
  },
  "subject_company": {
    "kbo": "0674.527.310",
    "name_full": "AgomAb Therapeutics",
    "legal_form": "NV",
    "is_foreign_registered": false
  },
  "capital_currency": "USD",
  "_currency_non_eur": true,
  "publication_proxy": {
    "kind": "notary",
    "org_kbo": null,
    "org_name": "Berquin Notarissen",
    "person_name": "Tim Carnewal"
  },
  "co_filed_documents": [
    "uitgifte/proces-verbaal van de akte",
    "aanwezigheidslijst",
    "aandelenoptieplan (2026 Globaal Aandelenoptieplan / 2026 ESOP Warrants voorwaarden)",
    "gecoordineerde tekst van statuten",
    "verslag van de raad van bestuur (art. 7:155, 7:179, 7:191 W.Venn.)",
    "verslag van de commissaris (art. 7:155, 7:179, 7:191 W.Venn.)",
    "verslag van de raad van bestuur (art. 7:180, 7:191 W.Venn.)",
    "verslag van de commissaris (art. 7:180, 7:191 W.Venn.)",
    "kapitalisatietabel"
  ],
  "shareholders_after": [],
  "share_classes_after": [
    {
      "n_shares": 48736779,
      "class_name": "gewone aandelen",
      "capital_share_eur": 300020250.16,
      "voting_rights_per_share": 1
    }
  ],
  "_claude_extraction_notes": "Single Staatsblad publication (numac 26313327, neergelegd 24-02-2026, published 26-02-2026) containing TWO co-filed notarial acts for AgomAb Therapeutics NV (KBO 0674.527.310), an IPO on Nasdaq. Notary Tim CARNEWAL, Berquin Notarissen, Brussel.\n\nACT 1 = BAV (buitengewone algemene vergadering) of 15 January 2026 with ELEVEN resolutions. These are AUTHORIZING/conditional decisions (subject to the Pre-IPO Opschortende Voorwaarde): 2nd=IPO kapitaalverhoging max EUR 300.000.000 incl agio with PR cancellation; 3rd=IPO Winstbewijs Conversie (Klasse A Preferent Winstbewijs \u2192 Gewone Aandelen ten gunste argenx BV, no issue price); 4th=IPO Aandelenconversie (all preferred A/B/C/D \u002B ESOP classes \u2192 ordinary, 1:1); 5th=confirmation cancellation Anti-Dilutie A/B/C/D Warrants; 6th=IPO Aandelensplitsing (ratio TBD); 7th=authorized capital (toegestaan kapitaal) authorization to RvB; 8th=statute changes; 9th=cancellation 4.552 (actual) unallocated warrants under \u00272024(B) Globaal Aandelenoptieplan\u0027; 10th=issuance new 2026 ESOP Warrants (5% fully-diluted); 11th=director remuneration.\n\nACT 2 = vaststellingsakte (IPO Closing) of 9 February 2026 by the IPO Comit\u00E9 delegate, crystallizing the conditional resolutions with ACTUAL numbers. Capital trajectory (capital constant through restructuring until the cash increase):\n- Before profit-cert conversion: EUR 223.071.500,16 / 876.522 shares (implied, fractiewaarde EUR 141,32).\n- B. IPO Winstbewijs Conversie: 95.616 new Gewone Aandelen created to argenx BV, NO issue price \u2192 capital UNCHANGED EUR 223.071.500,16, now 1.674.138 shares (fractiewaarde drops 141,32\u2192133,25).\n- C. IPO Aandelenconversie: Bevoorrechte D 342.206, C 455.004, B 479.040, A 277.272 \u002B ESOP all 1:1 \u2192 ordinary. Capital \u002B share count UNCHANGED (EUR 223.071.500,16 / 1.674.138).\n- D. Anti-Dilutie Warrants A/B/C/D cancellation confirmed (no capital effect).\n- E. IPO Aandelensplitsing: ratio 21,6450216450216 new per 1 old \u2192 1.674.138 \u2192 36.236.779 shares. Capital UNCHANGED EUR 223.071.500,16 (fractiewaarde 133,25\u21926,16).\n- F. IPO Kapitaalverhoging in geld: 12.500.000 new ordinary shares (each = 1 ADS) at USD 16,00 = USD 200.000.000,00 = EUR 169.577.751,40 (Wisselkoers EUR1=USD1,1794 on 6-2-2026). Allocated: EUR 76.948.750,00 to CAPITAL (delta), EUR 92.629.001,40 to uitgiftepremie (agio). Per share: ~EUR 6,16 capital \u002B ~EUR 7,41 agio. Result: capital EUR 300.020.250,16 / 48.736.779 fully-paid shares. Underwriters: J.P. Morgan Securities LLC, Morgan Stanley \u0026 Co. LLC, Leerink Partners LLC, Van Lanschot Kempen (USA) Inc. Funds USD 200M deposited at J.P. Morgan SE Brussels Branch (acct BE32549100985502), bankattest 9-2-2026.\n- G/H/I. Opschortende Voorwaarde fulfilled \u2192 authorized capital authorization (max EUR 300.020.250,16, 5yr) \u002B new statutes adopted.\n- J. 20.263 (actual) unallocated 2024(B) warrants cancelled.\n- K. 2.908.454 new 2026 ESOP Warrants issued (5% of 58.169.086 fully-diluted: 48.736.779 \u002B 6.523.853 existing-warrant shares \u002B 2.908.454 new ESOP).\n- L. Director remuneration fixed (USD amounts).\n\nEvents captured: (1) share_class_creation = IPO Winstbewijs Conversie (95.616 shares to argenx BV, no capital change); (2) share_class_conversion = IPO Aandelenconversie (all preferred\u2192ordinary, no capital change); (3) share_split = IPO Aandelensplitsing (1.674.138\u219236.236.779, no capital change); (4) capital_increase = IPO Kapitaalverhoging (delta EUR 76.948.750,00 capital \u002B agio EUR 92.629.001,40, 12.500.000 shares); (5) warrant_issuance = 2026 ESOP Warrants (2.908.454). Anti-Dilution warrant cancellation and the 20.263 unallocated warrant cancellation are warrant/inschrijvingsrechten events with no registered-capital effect (not capital_decrease \u2014 capital unchanged); noted but not material capital events; recorded warrant cancellation as \u0027other\u0027.\n\nSubscribers of the cash increase = the Underwriters (acting for ultimate subscribers / ADS holders), inschrijvingsformulier shows 12.500.000 shares subscribed total. No individual underwriter split of shares given. argenx BV is the recipient of the 95.616 conversion shares.\n\nNotary: Tim CARNEWAL, Brussel (eerste kanton), firm Berquin Notarissen (associated). Bedrijfsrevisor/commissaris reports referenced (art 7:155, 7:179, 7:191, 7:180) but firm/individual name NOT stated in text \u2192 null with waived=false. Pre-split share counts before conversion not all explicitly summed in the OCR (kapitalisatietabel was an annex, not reproduced); 876.522 pre-conversion count is implied from 1.674.138 - 95.616 \u002B the converted preferred totals, but the \u0027before\u0027 for the profit-cert conversion event is captured from the explicit constant capital EUR 223.071.500,16.",
  "_other_categories_present": [
    "statutes",
    "director_changes"
  ]
}

{
  "events": [
    {
      "kind": "capital_increase",
      "amount": 300000000.0,
      "currency": "EUR",
      "after_eur": null,
      "delta_eur": null,
      "before_eur": null,
      "amount_type": "kapitaal_toegestaan",
      "effective_date": "2026-01-15",
      "evidence_quote": "De buitengewone algemene aandeelhoudersvergadering van de Vennootschap besluit het kapitaal van de Vennootschap te verhogen met een bedrag van maximaal EUR 300.000.000,00 (inclusief uitgiftepremie) door de uitgifte van nieuwe gewone aandelen van de Vennootschap",
      "contribution_type": "cash"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0674.527.310",
    "name_full": "AGOMAB THERAPEUTICS",
    "legal_form": "NV"
  }
}

{
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "statute_change": {
    "name_change": true,
    "seat_change": false,
    "object_change": true,
    "effective_date": "2026-01-15",
    "legal_form_change": false
  },
  "bedrijfsrevisor": null,
  "subject_company": {
    "kbo": "0674.527.310",
    "name_full": "AGOMAB THERAPEUTICS",
    "legal_form": "NV"
  },
  "signature_regime": "joint_two",
  "special_mandates": [],
  "governance_change": {
    "admin_delegated_added": []
  }
}

{
  "events": [
    {
      "kind": "director_renew",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Ohad Hammer",
        "address": null,
        "birth_date": null
      },
      "evidence_quote": "De algemene vergadering beslist om de heer Ohad Hammer, die woonplaats kiest op de zetel van de Vennootschap, te herbenoemen als \u0022Klasse A Investeerder Bestuurder\u0022 voor een termijn van \u00E9\u00E9n jaar die een einde neemt onmiddellijk na de algemene vergadering te houden in 2026."
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0674.527.310",
    "name_full": "AGOMAB THERAPEUTICS",
    "legal_form": "NV"
  }
}

{
  "events": [
    {
      "kind": "director_renew",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "Ohad Hammer",
        "address": null,
        "birth_date": null,
        "profession": null,
        "birth_place": null
      },
      "reason": null,
      "subkind": "renewal",
      "via_org": null,
      "statutory": null,
      "compensated": false,
      "effective_date": null,
      "evidence_quote": "De algemene vergadering beslist om de heer Ohad Hammer, die woonplaats kiest op de zetel van de Vennootschap, te herbenoemen als \u0022Klasse A Investeerder Bestuurder\u0022 voor een termijn van \u00E9\u00E9n jaar die een einde neemt onmiddellijk na de algemene vergadering te houden in 2026. Het mandaat van de heer Ham",
      "decharge_status": null,
      "mandate_duration": {
        "kind": "n_years",
        "value": "1"
      },
      "rep_rotation_new_rep": null,
      "rep_rotation_old_rep": null,
      "effective_date_qualifier": null
    },
    {
      "kind": "delegation_dagelijks_bestuur_in",
      "role": "dagelijks_bestuur",
      "person": {
        "rrn": null,
        "name": "Ellen Lefever",
        "address": null,
        "birth_date": null,
        "profession": null,
        "birth_place": null
      },
      "reason": null,
      "subkind": "additional",
      "via_org": null,
      "statutory": null,
      "compensated": null,
      "effective_date": null,
      "evidence_quote": "De algemene vergadering beslist een bijzondere volmacht te verlenen aan elk van de bestuurders van de Vennootschap evenals aan Mevrouw Ellen Lefever, Mevrouw Silvana Hugue, Mevrouw Joni Oorts en de heer Mats Muys, allen individueel handelend en met het recht van indeplaatsstelling, teneinde alle for",
      "decharge_status": null,
      "mandate_duration": null,
      "rep_rotation_new_rep": null,
      "rep_rotation_old_rep": null,
      "effective_date_qualifier": null
    },
    {
      "kind": "delegation_dagelijks_bestuur_in",
      "role": "dagelijks_bestuur",
      "person": {
        "rrn": null,
        "name": "Silvana Hugue",
        "address": null,
        "birth_date": null,
        "profession": null,
        "birth_place": null
      },
      "reason": null,
      "subkind": "additional",
      "via_org": null,
      "statutory": null,
      "compensated": null,
      "effective_date": null,
      "evidence_quote": "De algemene vergadering beslist een bijzondere volmacht te verlenen aan elk van de bestuurders van de Vennootschap evenals aan Mevrouw Ellen Lefever, Mevrouw Silvana Hugue, Mevrouw Joni Oorts en de heer Mats Muys, allen individueel handelend en met het recht van indeplaatsstelling, teneinde alle for",
      "decharge_status": null,
      "mandate_duration": null,
      "rep_rotation_new_rep": null,
      "rep_rotation_old_rep": null,
      "effective_date_qualifier": null
    },
    {
      "kind": "delegation_dagelijks_bestuur_in",
      "role": "dagelijks_bestuur",
      "person": {
        "rrn": null,
        "name": "Joni Oorts",
        "address": null,
        "birth_date": null,
        "profession": null,
        "birth_place": null
      },
      "reason": null,
      "subkind": "additional",
      "via_org": null,
      "statutory": null,
      "compensated": null,
      "effective_date": null,
      "evidence_quote": "De algemene vergadering beslist een bijzondere volmacht te verlenen aan elk van de bestuurders van de Vennootschap evenals aan Mevrouw Ellen Lefever, Mevrouw Silvana Hugue, Mevrouw Joni Oorts en de heer Mats Muys, allen individueel handelend en met het recht van indeplaatsstelling, teneinde alle for",
      "decharge_status": null,
      "mandate_duration": null,
      "rep_rotation_new_rep": null,
      "rep_rotation_old_rep": null,
      "effective_date_qualifier": null
    },
    {
      "kind": "delegation_dagelijks_bestuur_in",
      "role": "dagelijks_bestuur",
      "person": {
        "rrn": null,
        "name": "Mats Muys",
        "address": null,
        "birth_date": null,
        "profession": null,
        "birth_place": null
      },
      "reason": null,
      "subkind": "additional",
      "via_org": null,
      "statutory": null,
      "compensated": null,
      "effective_date": null,
      "evidence_quote": "De algemene vergadering beslist een bijzondere volmacht te verlenen aan elk van de bestuurders van de Vennootschap evenals aan Mevrouw Ellen Lefever, Mevrouw Silvana Hugue, Mevrouw Joni Oorts en de heer Mats Muys, allen individueel handelend en met het recht van indeplaatsstelling, teneinde alle for",
      "decharge_status": null,
      "mandate_duration": null,
      "rep_rotation_new_rep": null,
      "rep_rotation_old_rep": null,
      "effective_date_qualifier": null
    }
  ],
  "notary": {
    "name": null,
    "firm_city": null,
    "firm_name": null,
    "office_city": "Antwerpen",
    "is_associated": false
  },
  "act_meta": {
    "language": "nl",
    "pub_date": "2025-06-17",
    "filing_date": "2025-06-05",
    "act_kind_objet": "Onderwerp akte:"
  },
  "decisions": [
    {
      "body": "algemene_vergadering",
      "date": "2025-05-30",
      "unanimous": null
    }
  ],
  "is_correction": false,
  "subject_company": {
    "kbo": "0674.527.310",
    "name_full": "Agomab Therapeutics",
    "legal_form": "NV"
  },
  "publication_proxy": {
    "kind": "person",
    "org_kbo": null,
    "org_name": null,
    "person_name": "Ellen Lefever",
    "org_rep_person_name": null,
    "person_role_at_subject": "Lasthebber"
  },
  "co_filed_documents": [],
  "corrected_publication_numac": null
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "Klasse A Investeerder Bestuurder",
      "person": {
        "rrn": null,
        "name": "Ohad Hammer",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0674.527.310",
    "name_full": "ivoluit Agomab Therapeutics"
  }
}

{
  "notary": {
    "name": "Tim CARNEWAL",
    "firm_city": null,
    "firm_name": "BERQUIN NOTARISSEN",
    "office_city": "Brussel",
    "is_associated": true
  },
  "act_meta": {
    "language": "nl",
    "pub_date": "2024-11-19",
    "filing_date": "2024-11-14",
    "act_kind_objet": "ONTSLAGEN, BENOEMINGEN, KAPITAAL, AANDELEN, STATUTEN (VERTALING, COORDINATIE, OVERIGE WIJZIGINGEN)"
  },
  "decision": {
    "body": "buitengewone_algemene_vergadering",
    "act_date": "2024-11-04",
    "unanimous": null
  },
  "statute_change": {
    "kinds": [
      "translation",
      "coordination",
      "full_restatement"
    ],
    "scope": "full_restatement",
    "trigger": "wvv_adaptation",
    "language_after": null,
    "language_before": null
  },
  "bedrijfsrevisor": null,
  "subject_company": {
    "kbo": "0674.527.310",
    "name_full_after": "AgomAb Therapeutics",
    "legal_form_after": "Naamloze vennootschap",
    "name_full_before": "AgomAb Therapeutics",
    "current_zetel_raw": "Posthoflei 1 bus 6 2600 Antwerpen",
    "legal_form_before": "Naamloze vennootschap"
  },
  "special_mandates": [],
  "articles_modified": [
    {
      "summary": "Wijziging van artikel 5 van de statuten om het in overeenstemming te brengen met de genomen beslissingen.",
      "new_text": null,
      "change_kind": "amended",
      "article_title": null,
      "article_number": "5"
    }
  ],
  "governance_change": {
    "organ_kind_after": null,
    "organ_kind_before": null,
    "admin_delegated_added": [
      {
        "name": "Pierre Kemula",
        "excluded_powers": []
      },
      {
        "name": "Ellen Lefever",
        "excluded_powers": []
      }
    ],
    "representation_rule_after": null,
    "co_signature_threshold_eur": null,
    "representation_rule_before": null
  },
  "publication_proxy": {
    "kind": "person",
    "org_kbo": null,
    "org_name": null,
    "person_name": "Tim CARNEWAL",
    "org_rep_person_name": null
  },
  "co_filed_documents": [
    "een uitgifte van het proces-verbaal",
    "aanwezigheidslijst",
    "vierentwintig volmachten",
    "de verslagen van de raad van bestuur en de commissaris opgesteld in toepassing van artikelen 7:155 en 7:180 van het Wetboek van vennootschappen en verenigingen",
    "bijlage Anti-Dilutie D Warrants",
    "de geco\u00F6rdineerde tekst van de statuten"
  ],
  "shareholder_rights": null,
  "voorwerp_change_summary": null,
  "capital_structure_change": {
    "operations": [
      "share_class_creation",
      "capital_increase_cash",
      "share_cancellation",
      "wvv_capital_release"
    ],
    "split_ratio": null,
    "shares_after": null,
    "shares_before": null,
    "capital_after_eur": 223071500.16,
    "capital_before_eur": 174712081.8,
    "share_classes_after": [
      {
        "count": 25000,
        "label": "Gewone Aandelen",
        "rights_summary": null,
        "voting_per_share": 1.0
      },
      {
        "count": 277272,
        "label": "Bevoorrechte A Aandelen",
        "rights_summary": null,
        "voting_per_share": 1.0
      },
      {
        "count": 479040,
        "label": "Bevoorrechte B Aandelen",
        "rights_summary": null,
        "voting_per_share": 1.0
      },
      {
        "count": 455004,
        "label": "Bevoorrechte C Aandelen",
        "rights_summary": null,
        "voting_per_share": 1.0
      },
      {
        "count": 342206,
        "label": "Bevoorrechte D Aandelen",
        "rights_summary": null,
        "voting_per_share": 1.0
      }
    ]
  },
  "coordinated_text_lineage": null
}

{
  "events": [
    {
      "kind": "capital_increase",
      "after_eur": 223071500.16,
      "delta_eur": 48359418.359999985,
      "before_eur": 174712081.8,
      "contribution_type": "geld"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0674.527.310",
    "name_full": "AgomAb Therapeutics"
  }
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "bestuurder",
      "person": {
        "rrn": null,
        "name": "BOND Colin Michael",
        "address": null,
        "birth_date": null
      },
      "effective_date": "2024-11-15",
      "evidence_quote": "De vergadering beslist te benoemen als Onafhankelijk Bestuurder, met ingang vanaf 15 November 2024 en voor een duur die zes jaar niet te boven gaat, de heer BOND Colin Michael, geboren te Maur (Zwitserland) op 26 januari 1960."
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0674.527.310",
    "name_full": "AGOMAB THERAPEUTICS",
    "legal_form": "NV"
  }
}

{
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "name_change": {
    "new": "",
    "old": "",
    "changed": false
  },
  "seat_change": {
    "changed": false
  },
  "object_change": {
    "changed": true
  },
  "subject_company": {
    "kbo": "0674.527.310",
    "name_full": "AgomAb Therapeutics"
  },
  "legal_form_change": {
    "new": "Naamloze vennootschap",
    "old": "Naamloze vennootschap",
    "changed": false
  }
}

{
  "events": [
    {
      "kind": "director_in",
      "role": "Onafhankelijk Bestuurder",
      "person": {
        "rrn": null,
        "name": "Colin Bond",
        "address": null,
        "birth_date": null
      }
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "extractor": "qwen3-30b-a3b"
  },
  "subject_company": {
    "kbo": "0674.527.310",
    "name_full": "AgomAb Therapeutics"
  }
}

{
  "events": [
    {
      "kind": "capital_increase",
      "amount": 48359418.36,
      "currency": "EUR",
      "after_eur": 223071500.16,
      "delta_eur": 48359418.36,
      "before_eur": 174712081.8,
      "amount_type": "kapitaal_effectief",
      "effective_date": "2024-11-04",
      "evidence_quote": "De vergadering beslist het kapitaal van de Vennootschap te verhogen met een bedrag van EUR 48.359.418,36 (exclusief uitgiftepremie), om het van EUR 174.712.081,80 te brengen op EUR 223.071.500,16, door inbreng in geld en met de uitgifte van 342.206 nieuwe Bevoorrechte D Aandelen",
      "contribution_type": "cash"
    }
  ],
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "subject_company": {
    "kbo": "0674.527.310",
    "name_full": "AGOMAB THERAPEUTICS",
    "legal_form": "NV"
  }
}

{
  "schema": "v3.2",
  "act_meta": {
    "model_id": 36,
    "extractor": "constrained-core-35b"
  },
  "statute_change": {
    "name_change": false,
    "seat_change": false,
    "object_change": false,
    "effective_date": "2024-11-04",
    "legal_form_change": false
  },
  "bedrijfsrevisor": null,
  "subject_company": {
    "kbo": "0674.527.310",
    "name_full": "AGOMAB THERAPEUTICS",
    "legal_form": "NV"
  },
  "signature_regime": "joint_two",
  "special_mandates": [],
  "governance_change": {
    "admin_delegated_added": []
  }
}